The Effect of Sugammadex on the Outcome After Colorectal Cancer Surgery
Sugammadex
1 other identifier
observational
585
1 country
1
Brief Summary
This study is retrospective study. The purpose of this study is checking the effect of sugammadex on the outcome after colorectal surgery. The outcome is compared among the 2 groups, sugammadex group and non-sugammadex group. The primary parameters of outcome are length of stay, readmission rate, postoperative complications, time interval for first successful oral intake.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2018
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 22, 2018
CompletedFirst Submitted
Initial submission to the registry
July 10, 2018
CompletedFirst Posted
Study publicly available on registry
August 8, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 31, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2018
CompletedAugust 20, 2019
August 1, 2019
5 months
July 10, 2018
August 18, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Length of stay
Length of stay in hospital
admission to discharge (within 1 month)
Secondary Outcomes (3)
Readmission rate
30 days after discharge
postoperative complication rate
after colorectal surgery, within 30 days
Time to first successful oral intake
within 30 days
Study Arms (2)
Sugammadex
Patients who used sugammadex Sugammadex 1 vial (200mg) intravenous, at the end surgery, before extubation
Non-sugammadex
Patients who didn't use sugammadex Pyridostigmine 15\~20mg intravenous, at the end of surgery, before extubation
Interventions
Sugammadex injection as a reverse agent of neuromuscular blocking
Eligibility Criteria
Patients aged 21 and 80 years old, who took the colorectal surgery due to colorectal cancer from Jan, 2012 to Dec, 2017
You may qualify if:
- Subjects aged 21\~80
- Subjects who took colorectal surgery due to colon or rectal cancer from Jan, 2012 to Dec, 2017
You may not qualify if:
- Emergency surgery
- Paraplegia or quadriplegia
- Bedridden state d/t various reason
- Neuromuscular disease
- Combined operation wth other surgery
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Ajou university school of medicine
Suwon, Gyeonggi-do, 16377, South Korea
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
In Kyong Yi, MD
Ajou University School of Medicine
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Clinical assistant professor
Study Record Dates
First Submitted
July 10, 2018
First Posted
August 8, 2018
Study Start
March 22, 2018
Primary Completion
August 31, 2018
Study Completion
September 1, 2018
Last Updated
August 20, 2019
Record last verified: 2019-08
Data Sharing
- IPD Sharing
- Will not share
No sharing